These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 25092729)

  • 1. Study supports routine lung tumor genotyping.
    Cancer Discov; 2014 Aug; 4(8):862-3. PubMed ID: 25092729
    [No Abstract]   [Full Text] [Related]  

  • 2. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
    Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma.
    Guibert N; Pradines A; Casanova A; Farella M; Keller L; Soria JC; Favre G; Mazières J
    J Thorac Oncol; 2016 Sep; 11(9):e109-12. PubMed ID: 27165943
    [No Abstract]   [Full Text] [Related]  

  • 4. Rare mutations in non-small-cell lung cancer.
    D'Arcangelo M; D'Incecco A; Cappuzzo F
    Future Oncol; 2013 May; 9(5):699-711. PubMed ID: 23647298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF mutations in non-small-cell lung cancer.
    Smit E
    J Thorac Oncol; 2014 Nov; 9(11):1594-5. PubMed ID: 25436793
    [No Abstract]   [Full Text] [Related]  

  • 6. Gene expression analysis in Merkel cell polyomavirus-positive non-small cell lung cancer from Japanese patients.
    Hashida Y; Imajoh M; Daibata M
    Int J Cancer; 2013 Dec; 133(12):3014-5. PubMed ID: 23740604
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular pathological findings of Merkel cell polyomavirus in lung cancer: a possible etiopathogenetic link?
    Antoniou KM; Lasithiotaki I; Symvoulakis E; Derdas SP; Psaraki A; Spandidos DA; Stathopoulos EN; Siafakas NM; Sourvinos G
    Int J Cancer; 2013 Dec; 133(12):3016-7. PubMed ID: 23740689
    [No Abstract]   [Full Text] [Related]  

  • 8. Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.
    Zhang XH; Shin JY; Kim JO; Oh JE; Yoon SA; Jung CK; Kang JH
    Cancer Lett; 2012 Sep; 322(2):213-22. PubMed ID: 22433711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF-mutations in non-small cell lung cancer.
    Brustugun OT; Khattak AM; Trømborg AK; Beigi M; Beiske K; Lund-Iversen M; Helland Å
    Lung Cancer; 2014 Apr; 84(1):36-8. PubMed ID: 24552757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF Mutations-A Good News Story for Immune Checkpoint Inhibitors in Oncogene-Addicted NSCLC?
    Arulananda S; Mitchell P
    J Thorac Oncol; 2018 Aug; 13(8):1055-1057. PubMed ID: 30056857
    [No Abstract]   [Full Text] [Related]  

  • 11. A SNaPshot into a tumor's genotype: rapid, comprehensive genotyping possible in routine clinical practice.
    Miller S
    Bioanalysis; 2011 Dec; 3(24):2705. PubMed ID: 22185268
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer.
    Tamiya A; Okamoto I; Miyazaki M; Shimizu S; Kitaichi M; Nakagawa K
    J Clin Oncol; 2013 Jan; 31(1):e15-7. PubMed ID: 23169500
    [No Abstract]   [Full Text] [Related]  

  • 13. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy.
    Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J
    Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.
    Riess JW; Wakelee HA
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):226-34. PubMed ID: 22706483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New driver mutations in non-small-cell lung cancer.
    Pao W; Girard N
    Lancet Oncol; 2011 Feb; 12(2):175-80. PubMed ID: 21277552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term gefitinib treatment of occult lung carcinoma with multiple brain metastases.
    Kobayashi T; Takeda M; Marumo S; Koshimo Y; Teranishi T; Higami Y; Kato M
    Lung Cancer; 2013 Apr; 80(1):109-11. PubMed ID: 23279871
    [No Abstract]   [Full Text] [Related]  

  • 17. ROS1-targeted therapy in non-small cell lung cancer.
    Sequist LV
    Clin Adv Hematol Oncol; 2012 Dec; 10(12):827-8. PubMed ID: 23271356
    [No Abstract]   [Full Text] [Related]  

  • 18. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.
    Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ
    J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824
    [No Abstract]   [Full Text] [Related]  

  • 19. Noninvasive monitoring of tumors.
    Schiller JH
    N Engl J Med; 2008 Jul; 359(4):418-20. PubMed ID: 18596267
    [No Abstract]   [Full Text] [Related]  

  • 20. A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations.
    Alrifai D; Popat S; Ahmed M; Gonzalez D; Nicholson AG; Parcq Jd; Benepal T
    Lung Cancer; 2013 Jun; 80(3):339-40. PubMed ID: 23499398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.